Bastiano Sanna - Oct 18, 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Cell & Genetic Therapies
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Oct 18, 2022
Transactions value $
-$537,860
Form type
4
Date filed
10/20/2022, 04:11 PM
Previous filing
Aug 3, 2022
Next filing
Nov 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale -$451K -1.5K -3.67% $300.02 39.5K Oct 18, 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$86.9K -288 -0.73% $301.84 39.2K Oct 18, 2022 Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1.
F2 Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $300.02 (range $300.00 to $300.14).
F4 Open market sales reported on this line occurred at a weighted average price of $301.84 (range $301.14 to $301.98).